Efficacy of Rimonabant and Other Cannabinoid CB1 Receptor Antagonists in Reducing Food Intake and Body Weight: Preclinical and Clinical Data

Mauro A. M. Carai, Giancarlo Colombo, Paola Maccioni, Gian Luigi Gessa
{"title":"Efficacy of Rimonabant and Other Cannabinoid CB1 Receptor Antagonists in Reducing Food Intake and Body Weight: Preclinical and Clinical Data","authors":"Mauro A. M. Carai,&nbsp;Giancarlo Colombo,&nbsp;Paola Maccioni,&nbsp;Gian Luigi Gessa","doi":"10.1111/j.1527-3458.2006.00091.x","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>The present paper focuses on the different lines of evidence indicating that cannabinoid CB<sub>1</sub> receptor antagonists, including the prototype rimonabant, reduce food intake and body weight in laboratory animals. Recent clinical surveys demonstrated that rimonabant significantly reduced body weight also in overweight/obese humans. Treatment with rimonabant was associated with a beneficial effect on different metabolic parameters and cardiovascular risk factors linked to overweight. The data reviewed in this paper suggest that cannabinoid CB<sub>1</sub> receptor antagonists may constitute a novel class of drugs potentially effective in the treatment of obesity-related disorders.</p>\n </div>","PeriodicalId":94307,"journal":{"name":"CNS drug reviews","volume":"12 2","pages":"91-99"},"PeriodicalIF":0.0000,"publicationDate":"2006-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1527-3458.2006.00091.x","citationCount":"46","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS drug reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2006.00091.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 46

Abstract

The present paper focuses on the different lines of evidence indicating that cannabinoid CB1 receptor antagonists, including the prototype rimonabant, reduce food intake and body weight in laboratory animals. Recent clinical surveys demonstrated that rimonabant significantly reduced body weight also in overweight/obese humans. Treatment with rimonabant was associated with a beneficial effect on different metabolic parameters and cardiovascular risk factors linked to overweight. The data reviewed in this paper suggest that cannabinoid CB1 receptor antagonists may constitute a novel class of drugs potentially effective in the treatment of obesity-related disorders.

利莫那班和其他大麻素CB1受体拮抗剂减少食物摄入和体重的疗效:临床前和临床数据
本论文着重于不同的证据表明大麻素CB1受体拮抗剂,包括原型利莫那班,减少食物摄入量和体重在实验动物。最近的临床调查表明,利莫那班也能显著减轻超重/肥胖人群的体重。利莫那班治疗对不同代谢参数和与超重相关的心血管危险因素有有益影响。本文回顾的数据表明,大麻素CB1受体拮抗剂可能构成一类潜在有效治疗肥胖相关疾病的新型药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信